Table 11.
Examples of EV use in preclinical studies related to the treatment of cancer.
| Source of EVs | Model | Major outcomes | References |
|---|---|---|---|
| Human BM-MSCs | In vitro | Inhibited proliferation and viability of HepG2, Kaposi, and Skov-3 cell lines |
(261) |
| In vivo murine cancer model | Inhibition of tumor growth | ||
| Escherichia coli combined with tumour cells | In vivo murine cancer model | Stimulated maturation of DCs Regression of tumor |
(262) |
| Murine melanoma cells combined with CpG oligos, TLR-9 agonist, and DCs-targeting aptamer | In vivo murine melanoma model | Stimulated maturation of DCs Stimulated specific activation of immune system against cancer |
(263) |
BM-MSCs, bone marrow MSCs; DCs, dendritic cells; HepG2, human liver cancer cell line; TLR-9, Toll-like receptor 9.